Bookmark and Share

$POAI Artificial Intelligence Could Help Eradicate COVID-19

The use of artificial intelligence (“AI”) has increased over the years. This has enabled researchers to have the computing powers of higher orders than what was there when COVID-19 first struck. Today, artificial intelligence has significantly been used to find different patterns within large information sets. Furthermore, artificial intelligence is instrumental in helping you to understand better any information that is not characterized. AI can also be used in predicting trends and patterns of the various phenomenon, and this could hold the key to finding a solution to COVID-19.

Incorporating Artificial Intelligence in COVID-19 research

Artificial intelligence works even better with a set of information that has been well characterized. It will help you in picking up trends and patterns, especially when dealing with well-organized sets of data. One laboratory has been using AI in building dynamic, physics-based protein models. The models are to help come up with molecules that can help eradicate COVID-19 viruses as they interact with cells. Additionally, chemistry studies are also capable of generating information that can be used with the AI that can create a tight loop between computing and experimental work

Researchers can, therefore, use artificial intelligence to peruse through thousands of possible therapies in-store to come up with something novel to fight the virus. Both the physics and chemistry methods can be used with Artificial Intelligence to come up with a concrete and complete solution. Benevolent Artificial Intelligence recently identified “baricitinib,” an arthritis drug, as a possible therapy for COVID-19. The drug is in a phase three trial and its results are yet to be received. The process of using an already approved drug, such as baricitinib, was for the procedure to be faster and straight forward to find a drug that could quickly fight the pandemic.

How AI will spur baricitinib as a potential remedy for COVID-19

Baricitinib has the potential to deal with coronavirus in two ways: it may stop some of the kinases that the virus is using to gain access into the human cells, and it may also help in moistening the immune system overreactions as it has been in severe COVID-19 cases. In a nutshell, this drug has both the anti-inflammatory and antiviral combination in it.

Benevolent Artificial Intelligence also revealed that the movement of baricitinib within the kidney and liver showed that it could be combined with other antivirals, such as Remdevisir, without causing adverse effect to those organs. Such bulk information and research could not be possible without the help of artificial intelligence, according to one researcher.

Use of AI to generate lead compounds

Some companies are also aiming to use artificial intelligence in creating a purpose-built molecule to fight COVID-19, and the process has already shown some success. AI can also be employed in every step of drug discovery, development and in the demographic analysis that can be used to track COVID-19. The company has used the structure of the virus obtained from the SARS outbreak in 2003 to begin its drug finding process. All this progress has been due to the use of AI, which is now looked at as a potent tool in this fight. It wouldn’t be surprising if other biomed companies, such as Predictive Oncology (NASDAQ: POAI), are already using AI in their own operations.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Wednesday, August 26th, 2020 Uncategorized
Top Small Cap Market News